12 Month Price Forecast For CTNM
Distance to CTNM Price Forecasts
CTNM Price Momentum
🤔 Considering Contineum (CTNM)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 8, 2025 9:53 AM UTC
CTNM Analyst Ratings & Price Targets
Based on our analysis of 4 Wall Street analysts, CTNM has a consensus that is bullish. The median price target is $30.00, with forecasts ranging from $25.00 to $32.00. Currently, there are 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
With CTNM currently trading at $8.41, the median price forecast suggests a 256.7% upside. The most optimistic forecast comes from Joel Beatty at Baird, projecting a 280.5% upside, while Jeffrey Hung at Morgan Stanley provides the most conservative target, suggesting a 197.3% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
CTNM Analyst Consensus
CTNM Price Target Range
Latest CTNM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for CTNM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Jan 9, 2025 | RBC Capital | Brian Abrahams | Outperform | Reiterates | $31.00 |
| Nov 7, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $31.00 |
| Oct 22, 2024 | Baird | Joel Beatty | Outperform | Initiates | $32.00 |
| Aug 14, 2024 | RBC Capital | Brian Abrahams | Outperform | Maintains | $32.00 |
| Apr 30, 2024 | RBC Capital | Brian Abrahams | Outperform | Initiates | $30.00 |
| Apr 30, 2024 | Morgan Stanley | Jeffrey Hung | Overweight | Initiates | $25.00 |
| Apr 30, 2024 | Stifel | Paul Matteis | Buy | Initiates | $29.00 |
Stocks Similar to Contineum Therapeutics, Inc. Class A Common Stock
The following stocks are similar to Contineum based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Financial Data
Contineum Therapeutics, Inc. Class A Common Stock has a market capitalization of $244.12M with a P/E ratio of 26.0x. The company generates $50.00M in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of +46.8% and return on equity of -20.8%.
Valuation Metrics
Growth & Margins
Financial Health
🔥 Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.
Contineum Therapeutics, Inc. Class A Common Stock (CTNM) Company Overview
About Contineum Therapeutics, Inc. Class A Common Stock
Develops novel oral therapies for neuroscience and inflammation.
Contineum Therapeutics, Inc. operates as a clinical stage biopharmaceutical company focusing on innovative therapies for conditions with significant unmet medical needs. The company generates potential revenue through the development of small molecule therapies, which can be monetized through partnerships, licensing agreements, and eventual commercialization after successful clinical trials.
The company's lead asset is PIPE-791, targeting conditions such as idiopathic pulmonary fibrosis and progressive multiple sclerosis. Contineum Therapeutics was formerly known as Pipeline Therapeutics and rebranded in November 2023. Founded in 2009, it is based in San Diego, California.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
31
CEO
Mr. Carmine N. Stengone MBA, MS
Country
United States
IPO Year
2024
Website
www.contineum-tx.comContineum Therapeutics, Inc. Class A Common Stock (CTNM) Latest News & Analysis
Contineum Therapeutics has completed enrollment of 168 patients in its Phase 2 PIPE-307 VISTA trial for its M1 receptor antagonist targeting relapsing-remitting multiple sclerosis.
Completion of patient enrollment in the PIPE-307 trial could signal progress towards potential FDA approval, impacting Contineum's stock value and market position in the biopharmaceutical sector.
Contineum Therapeutics (NASDAQ: CTNM) has initiated dosing for the first cohort of patients in its PIPE-791 Phase 1b trial, focusing on therapies for neuroscience and inflammation.
The start of patient dosing in a Phase 1b trial indicates progress in Contineum's drug development, potentially impacting future revenue and stock performance. Positive results may boost investor confidence.
Contineum Therapeutics, Inc. (NASDAQ: CTNM) will participate in a fireside chat at the 7th Annual Evercore HealthCONx, focusing on its oral therapies for neuroscience, inflammation, and immunology.
Contineum Therapeutics' participation in a prominent industry event highlights its visibility and potential for partnerships, which could impact its stock performance and investor sentiment.
Contineum Therapeutics (NASDAQ: CTNM) received FDA authorization for its Investigational New Drug application, advancing its development of oral therapies for neuroscience and immunology.
Authorization of Contineum's IND application signals progress in drug development, potentially increasing investor confidence and interest due to the company's focus on neuroscience and inflammation therapies.
Contineum Therapeutics (NASDAQ: CTNM) will attend investor conferences in November 2024, focusing on developing oral therapies for neuroscience, inflammation, and immunology.
Contineum Therapeutics' participation in investor conferences may signal potential growth and interest in their novel therapies, impacting investor sentiment and stock performance.
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
3 months agoContineum Therapeutics, Inc. (Nasdaq: CTNM) reported Q3 2024 financial results and highlighted corporate progress in developing therapies for neuroscience, inflammation, and immunology.
Contineum Therapeutics' financial results and corporate progress signal its potential for growth in the biopharmaceutical sector, affecting investor sentiment and stock valuation.
Frequently Asked Questions About CTNM Stock
What is Contineum Therapeutics, Inc. Class A Common Stock's (CTNM) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, Contineum Therapeutics, Inc. Class A Common Stock (CTNM) has a median price target of $30.00. The highest price target is $32.00 and the lowest is $25.00.
Is CTNM stock a good investment in 2025?
According to current analyst ratings, CTNM has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $8.41. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for CTNM stock?
Wall Street analysts predict CTNM stock could reach $30.00 in the next 12 months. This represents a 256.7% increase from the current price of $8.41. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Contineum Therapeutics, Inc. Class A Common Stock's business model?
Contineum Therapeutics, Inc. operates as a clinical stage biopharmaceutical company focusing on innovative therapies for conditions with significant unmet medical needs. The company generates potential revenue through the development of small molecule therapies, which can be monetized through partnerships, licensing agreements, and eventual commercialization after successful clinical trials.
What is the highest forecasted price for CTNM Contineum Therapeutics, Inc. Class A Common Stock?
The highest price target for CTNM is $32.00 from Joel Beatty at Baird, which represents a 280.5% increase from the current price of $8.41.
What is the lowest forecasted price for CTNM Contineum Therapeutics, Inc. Class A Common Stock?
The lowest price target for CTNM is $25.00 from Jeffrey Hung at Morgan Stanley, which represents a 197.3% increase from the current price of $8.41.
What is the overall CTNM consensus from analysts for Contineum Therapeutics, Inc. Class A Common Stock?
The overall analyst consensus for CTNM is bullish. Out of 4 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $30.00.
How accurate are CTNM stock price projections?
Stock price projections, including those for Contineum Therapeutics, Inc. Class A Common Stock, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
